Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas to Set Up New Panel on Global Management
February 6, 2015
- Eisai Discloses Option Rights for AD Treatment under Deal with Biogen Idec
February 6, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Daiichi Sankyo Initiates PIII Studies of Mirogabalin in Asia Including Japan
February 5, 2015
- Nipro’s Subsidiary to Build New Factory Eyeing Generic Market Expansion
February 5, 2015
- Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive
February 5, 2015
- Belsomra Again Grabs Number 1 Spot in December Anterio Ranking
February 4, 2015
- AbbVie Publishes Japanese PIII Study Results for Hepatitis C Treatment
February 4, 2015
- Astellas to Disclose Detailed Clinical Study Data on Approved Drugs
February 4, 2015
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
- Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
- Kyowa Hakko Bio Names Mr Kotani as New President
February 2, 2015
- Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions
January 30, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…